New radioactive drug targets Hard-to-Treat prostate cancer
NCT ID NCT06229366
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 35 times
Summary
This study tests a new radioactive drug called [Ac-225]-PSMA-62 in men with prostate cancer that has spread. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to find the safest dose and check for side effects in 142 participants with either hormone-sensitive or treatment-resistant cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Vancouver
Vancouver, V5Z4E6, Canada
-
Centre Hospitalier Universite de QUEBEC
Québec, G1J 1Z4, Canada
-
Hopital De Chicoutimi
Saguenay, G7H 5H6, Canada
-
Jewish General Hospital
Montreal, H3T 1E2, Canada
-
Juravinski
Hamilton, L8V 5C2, Canada
-
McGill University
Montreal, H4A 3J1, Canada
-
Princess Margaret Cancer Centre
Toronto, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.